Kerry has introduced Plenibiotic, its first-ever postbiotic ingredient, formulated from Lactobacillus casei subsp. 327 and designed to support digestive and skin health. Backed by randomized, double-blind, placebo-controlled trials, Plenibiotic targets the gut-skin axis, a growing focus among health-conscious consumers.
Key Features of Plenibiotic
Plenibiotic is a shelf-stable and low-dose formulation suitable for human and pet supplements. Its efficacy is achieved with just 50 mg for digestive or pet health and 100 mg for skin health. The ingredient’s versatility and tolerance to various environments make it ideal for a wide range of applications.
Kerry highlights the rising consumer interest in holistic wellness, noting that 75% of people prioritize healthy aging, with many beginning proactive care from age 30. Additionally, over half of those focused on digestive health also express interest in improving skin health.
Proactive Health Solutions
“Plenibiotic represents a major advancement in proactive health and wellness solutions,” said Jordan Dow, vice president of Kerry ProActive Health. “By leveraging science and sustainability, we’re creating innovative supplements that address key consumer needs.”
As reported by nutraceuticalsworld, this launch marks Kerry’s entry into the postbiotic market, complementing its existing probiotic portfolio, which includes BC30 and Sporevia. Plenibiotic is positioned to drive innovation in the supplements industry with its premium, clinically-supported benefits.